Correlation between quality of life indicators, peculiarities of diet and clinical manifestations of multiple sclerosis

Abstract

Multiple sclerosis is one of the most important problems of neurology. Onset age of disease is young, and young people, which are able to work often become invalids. That is why multiple sclerosis is medical and social problem. Questions of epidemiology and quality of life of our patients with multiple sclerosis are modern questions of multiple sclerosis problem. Our scientific work is devoted to relation between indicators of quality of life and dietary factors, clinical peculiarities of disease. We received interesting results. We found, that among males most important for quality of life are physical functions and common condition of health. And emotial problems, reduction of social functions, reduction of vitality are most important for quality of life among females.

Keywords

Bekhterev neurology archive

References

[1] Гусев Е.И., Демина Т.Л., Бойко А.Н. Рассеянный склероз. — М., 1997.

[2] Смирнова Н.Ф. Клинико-эпидемиологическое изучение роли внешних воздействий при PC: Автореф. дис. ... канд. мед. наук. — М., 1998.

[3] Татаринова М.Ю., Бойко А.Н., Смирнова Н.Ф., Алексеева Т.Г., Риизе Т., Нортвельдт М.В., Гусев Е.И. Показатели жизни больных рассеянным склерозом в зависимости от тяжести состояния //Материалы к республиканскому рабочему совещанию “Вопросы диагностики и лечения демиелинизирующих заболеваний нервной системы”, Ступино, 23 — 24 февраля 1999 г. — С.204 — 206

[4] Bowling A. Measuring disease. A review of disease-specific quality of life measurement scales. — Philadelphia, 1996.

[5] Cella D.F., Webster L. //Oncology. — 1996. — Vol. 12.-P.697-721.

[6] Kurtzke J.E. //Neuroepidemiology. — 1991. — Vol. 10.-P.1-8.

[7] Riise T., Boiko A., Granieri E. et al. //Neurology- August 1997. — Vol. 49. — № 2 (special suppl.).

[8] Razavi D., Gandek B. // J. Clin. Epid. — 1998. — Vol. 51.-P.975-983.

[9] Revicki D.A. Relationship of pharmacoeconomics and health-related quality of life //Quality of Life and Pharmacoeconomics in Clinical Trials /Ed. B. Spilker, 2nd ed. Philadelphia: Lippincott — Raven Publishers, 1996.-P.1077-1081.

[10] Smirnova N.F., Boiko A.N., Deomina T.L., Gusev E.L. //Multiple Sclerosis. — 1997. — Vol. 3. — P.285.

[11] Stacey J.H., Miocevich M.L., Sacks G.E. //Br. J. Clinic Pract. — 1996. — Vol. 50. — P.190 — 194.

[12] Tatarinova M.U., Boiko A.N., Alekseeva T.G. et al. // J. Multiple Sclerosis. — 1999. — Vol. 5. — P.142.

RIGHTS & PERMISSIONS

Tatarinova M.Y., Smirnova N.F., Boyko A.N.